About The Drug Neosalus Hydrating Topical Cream aka Neosalus Cream

ClusterMed

Find Neosalus Hydrating Topical Cream side effects, uses, warnings, interactions and indications. Neosalus Hydrating Topical Cream is also known as Neosalus Cream.

Neosalus Hydrating Topical Cream

Neosalus Hydrating Topical Cream Prescription Drug Bottle
About Neosalus Hydrating Topical Cream aka Neosalus Cream

What's The Definition Of The Medical Condition Neosalus Hydrating Topical Cream?

Clinical Pharmacology

CLINICAL PHARMACOLOGY No information provided.

Drug Description

NEOSALUS CREAM Hydrating Topical Cream For Topical Dermatological Use Only Prescription Medical Device Caution: Federal Law restricts this device to sale by, or on the order of a licensed healthcare practitioner. DESCRIPTION NEOSALUS CREAM is a fragrance-free, non-comedogenic water soluble dressing formulated for the management of various types of dermatoses, including atopic dermatitis and allergic contact dermatitis. Ingredients Carbomer, dimethicone, ethylparaben, glycerin, methylparaben, phenoxyethanol, polysorbate 20, povidone, propylene glycol, propylparaben, purified water, sodium hydroxide, stearic acid, trolamine.

Indications & Dosage

INDICATIONS NEOSALUS FOAM is indicated for management and relief of irritation experienced with various types of dermatoses, including atopic dermatitis and allergic contact dermatitis. DOSAGE AND ADMINISTRATION Directions For Use Apply to affected area three times a day unless otherwise directed by a prescribing healthcare practitioner. NEOSALUS FOAM should be rubbed gently into the skin until it is completely absorbed. Follow these important directions to ensure proper foaming and maximum delivery of product: Shake canister vigorously before each use. Turn upside down (nozzle down) to dispense. Depress ridged portion of dispenser, as illustrated at right. HOW SUPPLIED NEOSALUS FOAM is supplied in a 200 gram aerosolized canister bearing the NDC Number 23710-000-02, a 70 gram aerosolized canister bearing the NDC Number 23710-000-70, and a 10 gram aerosolized canister bearing the NDC Number 23710-000-01. Store at controlled room temperature 15° to 25°C (59° to 77°F). Contains flammable materials. Contents under pressure. Do not puncture and/or incinerate the containers. Do not expose to temperatures over 120°F (48°C) even when empty Manufactured for : Quinnova Pharmaceuticals LLC., Jamison, PA 18929 (877) 660-6263. Revised: Jan 2013

Medication Guide

PATIENT INFORMATION Directions For Use Apply to affected area three times a day unless otherwise directed by a prescribing healthcare practitioner. NEOSALUS FOAM should be rubbed gently into the skin until it is completely absorbed. Follow these important directions to ensure proper foaming and maximum delivery of product: Shake canister vigorously before each use. Turn upside down (nozzle down) to dispense. Depress ridged portion of dispenser, as illustrated at right.

Overdosage & Contraindications

OVERDOSE No information provided. CONTRAINDICATIONS Known hypersensitivity to any of the NEOSALUS FOAM ingredients.

Side Effects & Drug Interactions

SIDE EFFECTS No information provided. DRUG INTERACTIONS No information provided.

Warnings & Precautions

WARNINGS No information provided. PRECAUTIONS NEOSALUS FOAM is to be used only as directed by a healthcare practitioner. It should not be used to treat any condition other than that for which it is prescribed. For external use only. Avoid contact with the eyes, lips, and other mucous membranes. Exposure of the eye to NEOSALUS FOAM may result in reactions such as stinging and ocular irritation. If a reaction to NEOSALUS FOAM suggesting sensitivity or chemical irritation occurs, use of the medication should be discontinued and the prescribing healthcare practitioner consulted. This product provides no sunscreen protection. Use of sunscreen products and protective clothing over treated areas is recommended when exposure cannot be avoided. Certain temporary symptoms such as erythema, dryness, scaling, burning or pruritus may be experienced. These are most likely to occur during the first two to four weeks and will usually lessen with continued use of the medication. Depending upon the severity of the reaction patients should be instructed to reduce the frequency of application or discontinue use and to contact their prescribing healthcare practitioner. KEEP THIS AND OTHER MEDICATIONS OUT OF THE REACH OF CHILDREN.

More Medical Conditions

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

Medical Conditions Definitions Of The Day